A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 14, 2014

Primary Completion Date

April 24, 2017

Study Completion Date

November 7, 2017

Conditions

Aplastic Anemia

Interventions

DRUG

AMG531

Subcutaneous, weekly injection

Trial Locations (1)

Korea, Republic of, Seoul

All Listed Sponsors

lead

Kyowa Kirin Korea Co., Ltd.

INDUSTRY

NCT02094417 - A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia | Biotech Hunter | Biotech Hunter